FDA Urges Greater Focus on Contractor Quality - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA Urges Greater Focus on Contractor Quality
Outsourcing requires clear policies and written agreements with CMOs.

Pharmaceutical Technology
Volume 37, Issue 7, pp. 27-30

Jill Wechsler
The globalization of commercial drug production has increased reliance on vendors for raw materials and finished products, a situation that requires policies and systems to ensure that all parties understand responsibilities for meeting quality standards. FDA seeks to help manufacturers that hold market authorizations to maintain clear and effective relations with contractors through new guidance issued in May 2013 (1). The document encourages the use of written quality agreements (QAs) specifying contractor obligations to follow rules and implement quality processes.

The guidance document is the latest in a series of advisories, legislation, and compliance actions that address regulatory requirements for ensuring production of quality medicines. The FDA Safety & Innovation Act (FDASIA) of 2012 includes a provision (section 711) specifying that cGMPs include the implementation of quality oversight and controls over manufacture of drugs. This requirement applies to materials used in drug manufacturing, as well as finished products. Recent warning letters, moreover, emphasize that a manufacturer is responsible for infractions or noncompliance of its suppliers and vendors.

These actions reflect ongoing concerns about lax practices at contract manufacturing organizations (CMOs) that lead to drug shortages and delay approval of new drugs and biologics. Manufacturing difficulties at Lonza and at Boehringer Ingelheim's Ben Venue Laboratories have led to shortages in "essential" medicines. GlaxoSmithKline recently blamed CMO problems for shortages in its treatment for restless leg syndrome. In addition, FDA delayed approval of Allergan's new migraine therapy Levadex (dihydroergotamine) in April because of difficulties producing this inhaled product by Exemplar Pharma.

Clarifying relationships
FDA's guidance, Contract Manufacturing Arrangements for Drugs: Quality Agreements, provides specific strategies for manufacturers to ensure drug quality from third parties. The document maps ways to define and document the responsibilities of all parties involved in commercial production of human and animal drugs, biotechnology products, combination products, and APIs. The Office of Manufacturing and Product Quality (OMPQ) in the Center for Drug Evaluation and Research (CDER) prepared the guidance document in cooperation with staff from the Center for Biologics Evaluation and Research (CBER), the Center for Veterinary Medicine, and the Office of Regulatory Affairs. FDA encourages manufacturers to submit comments on the draft guidance by July 29, 2013, particularly examples of agreements and cases illuminating contracting issues.

FDA regulations don't require specific written agreements between pharmaceutical companies and third-party contractors, unlike the European Union, which mandates formal technical agreements between authorized manufacturers and all suppliers and contractors. FDA instead advises "owners" of a finished product to implement QAs with "contracted facilities" to clarify and document each party's obligations and responsibilities for ensuring compliance with GMPs and other regulations. FDA proposes that a QA stand separate from commercial contracts and specify the products or services involved, effective dates and termination, dispute resolution, and points of contact. A communication plan in the QA should explain processes for disclosing problems, such as how manufacturing deviations should be investigated, documented, and resolved. Change control is an important issue and requires clear procedures for handling new raw materials, establishment locations, manufacturing processes, testing procedures, manufacturing equipment, and other changes.

A main theme is that the owner of a new drug application is ultimately responsible for any failings or shortcomings by contractors. While all parties to a contract must prevent adulteration or misbranding, FDA emphasizes that owners cannot escape responsibility by pointing to vendor failings. Recent FDA warning letters to manufacturers of dietary supplements similarly cite legal precedents for holding the "final distributor" responsible for ensuring that its products comply with GMPs. In an April 26, 2013 warning letter to the owner of Pristine Bay LLC (Vianda) of Cincinnati, Ohio, FDA notes that although the firm may contract out certain manufacturing operations, "it cannot by the same token contract out its ultimate responsibility to ensure that the dietary supplements...are not adulterated" (2). While such statements are not new, attorneys Paul Hyman and Katie Bond of the lawfirm Hyman, Phelps, & McNamara, in the FDA Law Blog, comment that they are unusual in specifically citing the "Park doctrine" to bolster FDA warnings that a company and its officers might be held liable for acts by a third-party contractor (3).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here